Rick Scott Warns China's New Drug Rules Could Threaten U.S. Medicine Supply
Senator Rick Scott (R-Fla.) has raised concerns about new regulatory changes in China that could impact the U.S. pharmaceutical supply chain and complicate oversight by American regulators like the FDA. Scott criticized Beijing for passing rules he claims hinder transparency around medicines produced in China, making it harder for U.S. authorities to access critical information while still allowing those drugs to be sold domestically. He called on policymakers to reduce reliance on Chinese manufacturing for essential medications and advocated shifting production back to the United States. The warning follows broader scrutiny by U.S. lawmakers into potential biotechnology security risks associated with clinical trials in China, particularly at facilities linked to military or sensitive operations.
Topics: China FDA access Rick Scott U.S. pharmaceutical supply chain